New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

What it owns vs. what it owes Q4 FY2026, Jun 30, 2026

Shareholders’ equity is 37.1% of the balance sheet. What is a balance sheet?

Jun 30, 2026 · total $40.8M

Owns

$25.9MLong-term assets
$12.1MOther short-term assets
$2.8MCash & short-term investments

Funded by

$15.2MShareholders’ equity
$25.7MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 37.1%.

Older periods Dec '24 Jun '25 Dec '25 Jun '26
Total current assets
28.90 25.81 30.22 14.88
Total non-current assets
31.30 30.16 29.62 25.90
Total Assets
60.23 56.01 59.85 40.81
Total current liabilities
8.56 9.67 10.04 12.83
Total non-current liabilities
17.79 18.57 17.02 12.84
Total liabilities
26.35 28.24 27.06 25.66
Common Equity (Total)
33.88 27.76 32.78 15.15
Shareholders Equity (Total)
33.88 27.76 32.78 15.15

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026